Pharmaceutical molecules usually cross three continents during their production process, before they find their way to the patient. These drugs are produced and isolated in several steps, requiring often different production sites for each activity. This complex process leads to great vulnerability, as many factors can affect the production process (such as the COVID-19 pandemic, environmental disasters and geopolitical conflicts). Furthermore, traditional fine chemical synthesis is accompanied with a large waste stream which has become an environmental burden. But what if we could produce these drugs in a single, European site, at a high scale and in a sustainable fashion?